Curis Inc
NASDAQ:CRIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shaanxi Meineng Clean Energy Corp Ltd
SZSE:001299
|
CN |
|
T
|
Twentyfirst Century Management Services Ltd
NSE:21STCENMGM
|
IN |
|
B
|
BuzzFeed Inc
NASDAQ:BZFD
|
US |
|
X
|
XiAn International Medical Investment Co Ltd
SZSE:000516
|
CN |
|
S
|
Shenzhen Aoni Electronic Co Ltd
SZSE:301189
|
CN |
Curis Inc
Common Stock
Curis Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Curis Inc
NASDAQ:CRIS
|
Common Stock
$129k
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
$1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Curis Inc
Glance View
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
See Also
What is Curis Inc's Common Stock?
Common Stock
129k
USD
Based on the financial report for Dec 31, 2025, Curis Inc's Common Stock amounts to 129k USD.
What is Curis Inc's Common Stock growth rate?
Common Stock CAGR 10Y
-21%
Over the last year, the Common Stock growth was 52%. The average annual Common Stock growth rates for Curis Inc have been -49% over the past three years , -32% over the past five years , and -21% over the past ten years .
